Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review_West China Medical Journal

Authors：

Department of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China;

Corresponding?author：

Keywords：

硼替佐米; 多發性骨髓瘤; 治療; 外周血干細胞采集

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的：探討蛋白酶體抑制劑——硼替佐米對初治多發性骨髓瘤的療效及對移植造血干細胞采集的影響。方法：對一例初發的中年男性多發性骨髓瘤患者使用硼替佐米+地塞米松+反應停（VTD）的方案進行化療，獲得緩解后采集外周血造血干細胞。結果：應用以硼替佐米為基礎的方案治療3個療程后，患者即獲得完全緩解；完成4個療程化療后成功采集足夠數量的外周血造血干細胞；完成6個療程化療后，進入維持治療，至今已完全緩解17個月。治療過程中除惡心、嘔吐外無其他明顯不良反應。結論：硼替佐米用于初治多發性骨髓瘤有良好的治療效果，不良反應少，不影響造血干細胞采集。

Citation： LIU Zhigang,NIU Ting,LIU Wei,et al. Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review. West China Medical Journal, 2008, 23(1): 73-74. doi: Copy

1.	[11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
2.	[12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
3.	[13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
4.	[14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
5.	[15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
6.	[16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
7.	Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
8.	Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
9.	Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
10.	Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
11.	O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
12.	Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
13.	Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
14.	Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
15.	Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
16.	Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.

1. [11]Richardson PG,Sonneveld P,Schuster MW,et al.Bortezomib or High-Dose Dexa methasone for Relapsed Multiple Myeloma[J].N Engl J Med,2005,352:2487-98.
2. [12]Richardson PG,Chanan-Khan A,Schlossman R,et al.A multicenter phase Ⅱ trial of bortezomib in Patients with previously untreated multiple myeloma:efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy[J].Blood,2005,106:2548.
3. [13]Wang LM,Weber DM,Delasalle KB,et al.VTD (Velcade,Thelidomide,Dexamethaso me) as primary therapy for newly-diagnosed multiple myeloma[J].Blood,2004,104:210.
4. [14]Harousseau JL,Attal M,Leleu X,et al.Bortezomib(Velcade)plus decamethas one as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Blood,2004,104:1490.
5. [15]Peles S,Fisher NM,Devine SM,et al.Bortezomib(velcade)when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV)[J].Blood,2005,106:3237.
6. [16]Geoffrey LU,Fisher NM,Devine SM,et al.Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma[J].Blood,2005,106:2926.
7. Adams J.The proteasome:structure,function,and role in the cell[J].Cancer Treat Rev,2003,29(suppl 1)3-9.
8. Kyle RA,Rajkumar SV.Drug therapy of multiple myeloma[J].N Engl J Med,2004,351:1860-73.
9. Voorhees PM,Dees EC,O’Neil B,et al.The proteasome as a target for cancer therapy[J].Clin Cancer Res,2003,9:6316-25.
10. Richardson PG,Mitsiades C.Bortezomib:proteasome inhibition as an effective anticancer therapy[J].Annu Rev Med,2006,57:33-47.
11. O’Connor OA.Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell ly mphoma[J].Clin Lymphoma Myeloma,2005,6(3):191-9.
12. Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyelomaactivity of proteasome inhibitor PS-341[J].Blood,2003,101:1530.
13. Roccaro AM,Hideshima T,Raje N,et al.Bortezomib targets multiple myeloma endothelial cells[J].Blood,2004,104:4903.
14. Heider U,Kaiser M,Muller C,et al.Treatment of bortezomib increases osteoblast function in patients with multiple myeloma[J].Blood,2005,106:3457.
15. Richardson PG,Barlogie B,Berenson J,et al.A phase 2study of bortezomib in relapsed,refractory myeloma[J].N Engl J Med,2003,348:2609-17.
16. Blade J,Samson D,Reece D,et al.Criteria for evaluating disease response and progressionin patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation[J].Br J Haematol,1998,102:1115-23.

West China Medical Journal

Report of An Early Case of Multiple Myeloma Treated by Bortezomib and the Literature Review

Abstract Full text Figures/Tables Video References Cited by

Format

Content